The team, working with young and aged C57BL/6J mice, began by confirming what epidemiological studies had long hinted at. Auditory brainstem response testing showed that 85 percent of the aged animals failed to respond to sounds below 70 decibels, with click-evoked and frequency-specific thresholds markedly elevated across the 4 to 32 kilohertz range. Distortion product otoacoustic emissions were also impaired at high frequencies, indicating that the cochlea’s mechanical amplifier had faltered alongside its neural signaling. In short, these mice were a faithful model of human presbycusis.

To find out what was happening at the cellular level, the investigators isolated pericytes from the stria vascularis, the metabolically ravenous, ribbon-like structure that powers the cochlea and houses the blood-labyrinth barrier. Using fluorescence-activated cell sorting to purify pericytes marked by PDGFR-beta, they performed transcriptome sequencing on cells from young and aged mice. The results were striking: both Igf1 and Slc25a33, a gene encoding a mitochondrial nucleotide carrier, were significantly downregulated in the aged pericytes. Pathway enrichment analyses flagged the TGF-beta signaling pathway as one of the most differentially activated routes in the aging cells, alongside terms linked to cell junctions and the cytoskeleton.

Immunofluorescence staining of cochlear sections confirmed the story in tissue. IGF-1 and SLC25A33 proteins, which normally co-localize within the stria vascularis, showed a pronounced age-dependent decline, and the change was most dramatic in pericytes themselves. Critically, the levels of the IGF-1 receptor did not differ between young and aged pericytes, suggesting that the defect lies in the supply of the hormone rather than in the cell’s ability to sense it. When the researchers blocked IGF-1 signaling in cultured human brain vascular pericytes with the inhibitor NVP-AEW541, SLC25A33 messenger RNA and protein both fell; adding recombinant IGF-1 pushed them back up. Endothelial cells, by contrast, did not respond in the same way, marking pericytes as the specific cellular target of this regulatory axis.

Why would losing SLC25A33 matter so much? The protein is a mitochondrial carrier that helps sustain oxidative phosphorylation and redox balance. When the team silenced Slc25a33 with shRNA, flow cytometry using MitoSOX Red revealed a surge in mitochondrial reactive oxygen species leaking from the electron transport chain. The pericytes then began to change character. Alpha-smooth muscle actin, the signature of a contractile, myofibroblast-like state, rose sharply at both the messenger RNA and protein levels, while E-cadherin, a junctional protein associated with quiescent, barrier-stabilizing pericytes, dropped. The cells were undergoing a phenotypic switch from quiet vascular support cells into activated, fibrosis-prone contractile cells.

The mechanistic thread connecting these events proved to be TGF-beta signaling. In SLC25A33-deficient pericytes, TGF-beta messenger RNA and protein were elevated, and phosphorylated Smad2, the activated form of the transcriptional mediator, increased robustly. Total Smad2, Smad3, and Smad4 levels were unchanged, and phosphorylated Smad3 did not budge, indicating a selective engagement of the canonical Smad2 arm. When the researchers treated the deficient cells with MitoTEMPO, a mitochondrial antioxidant, the excess reactive oxygen species fell and TGF-beta, phospho-Smad2, and alpha-SMA all declined, placing mitochondrial oxidative stress upstream of the signaling cascade. Conversely, blocking the TGF-beta receptor with LY2109761 restored E-cadherin and suppressed the contractile markers, confirming that the pathway mediates the differentiation program.

The decisive test came in living animals. Delivering recombinant IGF-1 directly into the cochlea of aged mice through the round window membrane boosted SLC25A33 expression in the stria vascularis, while the IGF-1 inhibitor deepened its decline. Using adeno-associated virus vectors tailored for inner ear transduction, the team then overexpressed or knocked down Slc25a33 in the aged cochlea. Overexpression reduced alpha-SMA and TGF-beta signaling and raised E-cadherin; knockdown did the opposite. Transmission electron microscopy laid bare the structural consequences: in IGF-1-suppressed mice, pericytes showed abnormal morphology, loose associations with endothelial cells, and widened tight junctions, hallmarks of a leaky blood-labyrinth barrier. Exogenous IGF-1 preserved those intimate pericyte-endothelial contacts and restored tight junction integrity.

Most importantly for patients, the intervention worked functionally. IGF-1 supplementation significantly lowered click-evoked auditory brainstem response thresholds in aged mice, and at 12 kilohertz the treated animals heard markedly better than both untreated and IGF-1-suppressed controls. In mice whose Slc25a33 had been silenced by viral knockdown, treatment with the TGF-beta receptor inhibitor LY2109761 raised levels of the tight junction proteins Claudin-5 and Occludin in the stria vascularis, easing barrier disruption. The findings were further validated in an independent mouse strain, CBA/CaJ, where aged animals likewise showed reduced IGF-1 and SLC25A33 protein in the stria vascularis, indicating that the mechanism generalizes across genetic backgrounds.

The study thereby assembles a complete causal chain: aging lowers IGF-1, which suppresses the mitochondrial carrier SLC25A33 in strial pericytes; mitochondrial reactive oxygen species accumulate; the TGF-beta/Smad2 pathway activates; pericytes transform into contractile, pro-fibrotic cells; the blood-labyrinth barrier breaks down; and hearing deteriorates. This mirrors the pericyte-to-myofibroblast transitions documented at the blood-brain barrier, where elevated alpha-SMA similarly undermines vascular stability, and it echoes the ROS-driven epithelial-to-mesenchymal transitions long observed in other tissues. The cochlea, with its extraordinarily high metabolic demand and dense mitochondrial population, appears uniquely vulnerable to this failure mode.

Questions remain before the discovery can be translated into therapy. Whether IGF-1 acts directly on pericytes through its receptor or partly through paracrine networks will require cell-specific knockout models, and IGF-1 almost certainly regulates additional mitochondrial and cytoprotective genes that contribute to barrier stability. Species differences between human and mouse pericytes also warrant caution. Still, the identification of SLC25A33 as a biomarker and potential drug target, and the demonstration that both hormone supplementation and TGF-beta blockade can partially rescue barrier structure and auditory function in aged animals, opens a genuinely new frontier. If future work confirms the axis in humans, protecting the inner ear’s microscopic vasculature could become a strategy for preserving hearing in a rapidly aging world population.

Subject of Research: The IGF-1/SLC25A33 regulation of blood-labyrinth barrier pericytes in age-related hearing loss

Article Title: IGF‐1/SLC25A33 Maintains Blood‐Labyrinth Barrier Integrity by Suppressing TGF‐β/Smad2‐Mediated Pericyte Activation in Age‐Related Hearing Loss

Article References: Xu, R., Tang, J., Lin, H., Li, Q., Feng, Y., Zhang, X., Hu, X., Yang, J., Li, Y., & Bai, Y. (2026). IGF ‐1/ SLC25A33 Maintains Blood‐Labyrinth Barrier Integrity by Suppressing TGF ‐β/Smad2‐Mediated Pericyte Activation in Age‐Related Hearing Loss. Aging Cell, 25(10), Article e70712. https://doi.org/10.1111/acel.70712

Image Credits: AI Generated

DOI: 10.1111/acel.70712

Keywords: age-related hearing loss, IGF-1, SLC25A33, pericytes, blood-labyrinth barrier, TGF-beta, Smad2, mitochondrial ROS, stria vascularis, presbycusis, cochlea, Aging Cell

The study focuses on a chemical tag known as N6-methyladenosine, or m6A, the most abundant internal modification found in messenger RNA. m6A marks are deposited by a family of writer enzymes, of which METTL3 is the principal methyltransferase, and they influence nearly every stage of an RNA molecule’s life, from processing and export to translation and decay. Because m6A modification has already been implicated in a wide range of aging-related diseases, the Chinese team reasoned that it might also play a role in the cochlea, where aging is accompanied by a slow-burning inflammatory state often described as inflammaging. What they found was a strikingly specific protective circuit linking RNA chemistry to the immune response.

To model the disease, the researchers used twelve-month-old C57BL/6 mice, a strain in which hearing loss develops predictably with age, and an in vitro system in which HEI-OC1 auditory cells were stressed with lipopolysaccharide, a bacterial inflammatory trigger, and D-galactose, a sugar that induces senescence-like damage in cells. Auditory function was quantified using auditory brainstem response testing, which measures how effectively the auditory nerve relays sound signals to the brain, while cochlear structure was examined with hematoxylin-eosin staining. Inflammatory signaling was tracked with enzyme-linked immunosorbent assays, quantitative PCR, Western blotting, and immunofluorescence, giving the team a multi-layered picture of gene expression, protein abundance, and cellular localization.

The first key observation was that two molecules were significantly depleted in the cochleae of the aging mice: METTL3 itself, and NFKBIA, the gene encoding nuclear factor-kappaB inhibitor alpha, the protein that keeps the master inflammatory transcription factor NF-κB locked in an inactive state. NF-κB is a central switch in the immune system; when it is released from its inhibitor, it enters the nucleus and switches on a battery of pro-inflammatory genes, including interleukin-6 and components of the NLRP3 inflammasome, a multiprotein complex that drives a highly destructive form of inflammatory cell death called pyroptosis. With NFKBIA levels falling in the aged cochlea, this braking system weakens, allowing the NF-κB/IL-6/STAT3 axis and the NLRP3 inflammasome to fire unchecked.

The team then tested what happens when each component is manipulated. In HEI-OC1 cells, overexpressing NFKBIA suppressed both the NLRP3 inflammasome and the pro-inflammatory NF-κB/IL-6/STAT3 cascade, confirming that this inhibitor acts as a genuine gatekeeper of cochlear inflammation. Conversely, when the researchers boosted METTL3, NF-κB-mediated inflammation subsided, but that protective effect was largely abolished when NFKBIA was knocked down with silencing techniques. This dependency revealed the order of operations: METTL3 does not calm inflammation directly; it does so by keeping NFKBIA abundant, and NFKBIA in turn restrains NF-κB and everything downstream of it.

The mechanistic core of the paper lies in how METTL3 sustains NFKBIA. Using RNA immunoprecipitation combined with quantitative PCR, the researchers showed that METTL3 physically binds to NFKBIA messenger RNA. Using an m6A RNA methylation quantification kit and RNA stability assays, they demonstrated that this binding deposits m6A marks on the transcript and thereby enhances its stability, meaning the message survives longer in the cell and yields more of the inhibitory protein. In other words, METTL3 protects hearing not by changing the genome, but by chemically tuning how long a single anti-inflammatory message persists, a subtle epitranscriptomic intervention with outsized consequences for the inflammatory state of the inner ear.

The decisive experiment came in living animals. When the researchers overexpressed METTL3 in the ARHL mice, NFKBIA levels in the cochlea were restored, auditory brainstem response thresholds improved, and cochlear pathology visible under the microscope was ameliorated. At the molecular level, activation of the NLRP3 inflammasome and the NF-κB/IL-6/STAT3 pathway was suppressed, along with the downstream pyroptotic machinery marked by the gasdermin D-N domain. Taken together, the results trace a complete causal chain from an RNA methyltransferase, through m6A modification of a specific transcript, through a stabilized inhibitor of NF-κB, to reduced inflammatory signaling, preserved cochlear architecture, and better hearing in aged animals.

The significance of this work extends beyond otolaryngology. Chronic low-grade inflammation is now recognized as a shared driver of many age-related conditions, from cardiovascular disease to diabetes and neurodegeneration, and the NF-κB/IL-6/STAT3/NLRP3 axis identified here is a recurring motif across those disorders. Prior studies have shown that m6A modification maintains epithelial homeostasis in the colon through NF-κB signaling, and that other m6A regulators such as ALKBH5 can relieve neuroinflammation by increasing NFKBIA. The new findings place the aging cochlea squarely within this emerging framework, and they suggest that epitranscriptomic therapies, designed to adjust RNA methylation patterns rather than DNA sequences, could offer a way to dampen inflammaging in vulnerable tissues with considerable precision.

Important caveats remain before such a therapy could reach patients. The mouse model, while standard for presbycusis research, does not capture the full complexity of human hearing loss, which is shaped by genetics, noise exposure, vascular health, and lifestyle. Delivering METTL3 or its mRNA to the delicate structures of the inner ear poses formidable technical challenges, and globally enhancing m6A modification carries risks, since the same marks regulate thousands of transcripts, including some involved in cancer and immune function. The authors note that the datasets used in the study are available from the corresponding author on reasonable request, and the work was supported by the National Natural Science Foundation of China and a clinical research program of the Third Affiliated Hospital of Sun Yat-sen University.

Even so, the study offers something the field has lacked: a concrete, mechanistically validated molecular target for a condition long considered an inevitable consequence of growing old. If future work confirms that boosting METTL3 activity, or mimicking its effect on NFKBIA, is safe and feasible in humans, the era of treating age-related hearing loss with drugs rather than devices may come one step closer. For now, the message from Guangzhou is a compelling one: the difference between an aging ear that fails and one that endures may lie, in part, in a single methyl group attached to a single strand of messenger RNA.

Subject of Research: The role of METTL3-mediated m6A modification of NFKBIA in suppressing NF-κB-mediated inflammation in age-related hearing loss

Article Title: METTL3 mitigates age-related hearing loss by inhibiting NF-κB-mediated inflammatory responses through the m6A modification of NFKBIA

Article References: Tan, J., Luo, J., Li, L., Chen, D., Wang, J., Ge, C., & Li, P. (2026). METTL3 mitigates age-related hearing loss by inhibiting NF-κB-mediated inflammatory responses through the m6A modification of NFKBIA. Journal of Molecular Medicine, 104(1), Article 107. https://doi.org/10.1007/s00109-026-02714-5

Image Credits: AI Generated

DOI: 10.1007/s00109-026-02714-5

Keywords: age-related hearing loss, METTL3, NFKBIA, m6A modification, NF-κB, NLRP3 inflammasome, inflammaging, cochlea, RNA methylation, IL-6, STAT3, presbycusis